Stimulating innovative research

In 2021, we are offering a series of research grants to stimulate innovative research in challenging areas of future importance. Grants of 40,000 € - 450,000 € per year for up to 3 years are available in the areas as further specified below.

  • 药物发现-3赠款,包括350,000欧元,共3年,并选择扩展。
  • 实时测试和传感器- 赠款包括100,000-500,000 $/年2年,可以选择扩展
  • 核酸递送的纳米颗粒 -赠款包括100,000-300,000 $/年2年,可以选择扩展
  • 数字创新 -3赠款,包括40,000-100,000欧元1年,并选择扩展
  • 生物电子学-赠款包含150,000欧元/年3年
  • 可持续性- grant/s to be negotiated on a case by case basis
  • Media recycling for cultured meat- grant/s to be negotiated on a case by case basis
  • Organoids- grant/s to be negotiated on a case by case basis



Submission deadline was 31 August 2021.

Deep dive Workshops


识别和描述th邀请建议e next game-changing molecule or technology to help cure cancer or autoimmune disease. What are new breakthrough enabling technologies for drug discovery, e.g. single cell sequencing? Which molecular targets or pathophysiological pathways have untapped potential to deliver the next big therapeutic breakthrough? Where is upside potential for other indications e.g. in antiviral activity and pandemic preparedness? How can translation and predictivity of preclinical models to the clinical situation be enhanced, can quantitative methods (e.g. PK/PD, QSP, AI/ML) enable this? How can our evolving understanding of senescence and age-related changes be translated into drug discovery approaches?

We are seeking research proposals that can substantially advance the state-of-the-art of in-line or at-line monitoring during the production of biopharmaceuticals with the ultimate goal being real-time release. Technologies may include: rapid microbiological testing for detection of bacteria, viruses, endotoxins (e.g. nucleic acid based, optical or spectroscopic technologies that can be validated); Sterile sampling: rapid, automated, flexible technologies for batch and continuous processes; In-line detection of protein aggregates that can be validated; Automated data processing technologies to support complex analytics that can enable electronic batch record creation (e.g. machine learning for mass spectrometry and chromatography data).

Various existing nucleic acid delivery technologies, such as (lipid) nanoparticles are ripe for innovation. We seek new technologies and approaches for novel inventive delivery vehicles and formulations, routes of delivery, and targeting strategies. Equally important is the impact of nucleic-acid molecular properties and formulation composition on subsequent manufacturing processes, storage conditions and in vivo stability. What innovative materials can be used for nucleic-acid delivery? How to go beyond the liver? What targeting methods can be used to deliver nucleic-acid highly selective to different tissues? How can the biocompatibility of such carriers be improved? What formulation parameters can be tapped to improve stability/storage?

研究Grants for Digital Innovation leveraging technological solutions such as digital pathology image analysis for advanced cell simulation, Big Data and X-Omics pipelines for single-cell RNASeQ Analysis and other applications of AI in R&D. We are seeking 1. proposals for a digital image analysis pipeline for advanced cell simulation to improve quantification of DAB immune-reactivity in FFPE stained tumor tissue 2. proposals for computational tools which specifically exploit RNASeQ data from treated samples to understand pathway biology and immune mechanisms 3. other applications of AI in R&D.

The Bioelectronics program aims to develop new medical devices for chronic indications with high unmet medical need. For us, Bioelectronics also offers an entry point to enhance treatment outcomes through digital interfaces which continuously gather and analyse multiple biosensor data. In order to extend our capabilities for this emerging field of Bioelectronics, we are looking for novel solutions allowing remote patient monitoring or proprietary biosensor technologies to support patients. Specifically, we are interested in patient management solutions for patients of multiple sclerosis (MS), rheumatoid arthritis and other chronic inflammatory disorders.

培养的肉类生产过程目前严重依赖于为生物制药工业开发的技术,并且需要在生物药物中尚未看到的生物处理方面的新效率。细胞培养基是过程效率最重要的杠杆之一,因此是最终培养的肉类消费产品的成本。回收策略已成功地应用于许多领域,但我们仍然缺少解决大规模回收细胞培养基的解决方案。建议应解决概念设计,部署策略,低成本和高效的工业规模培养基媒体回收系统的设备,以促进养分有效使用以及去除有毒 /生长的抑制代谢物


We are on a journey to develop and provide more sustainable solutions to guarantee future success and create lasting value for society. We focus on four key aspects: circular economy, digitizing sustainability, responsible & new resources and new bio routes to achieve sustainability in our own processes and enable our customers and stakeholders in theirs. Proposals shall target at least one of the above-mentioned key aspects and consider the social, environmental and economic facet of sustainability by proposing new sustainable products, technologies, sources, processes and business models. Your proposal should consider that we are a a science-driven organization active in healthcare, life science and performance materials sectors.